MX2007005159A - Derivados de pirimidina biciclicos inhibidores del vih. - Google Patents

Derivados de pirimidina biciclicos inhibidores del vih.

Info

Publication number
MX2007005159A
MX2007005159A MX2007005159A MX2007005159A MX2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A MX 2007005159 A MX2007005159 A MX 2007005159A
Authority
MX
Mexico
Prior art keywords
substituted
6alkyl
amino
optionally substituted
6alkyloxy
Prior art date
Application number
MX2007005159A
Other languages
English (en)
Inventor
Jan Heeres
Paulus Joannes Lewi
Jerome Emile Georges Guillemont
Paul Adriaan Jan Janssen
Mikael Paugam
Bruno Francois Marie Delest
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2007005159A publication Critical patent/MX2007005159A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Abstract

Inhibidores de replicacion del VIH de formula (ve formula) N-oxidos, sales de adicion farmaceuticamente aceptables, aminas cuaternarias o sus formas estereoisomericas, en los cuales -a1=a2-a3=a4-es -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH-; -b1=b2-b3=b4- es -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH-; n y m es 0, 1, 2, 3 y en ciertos casos tambien 4,R1 es hidrogeno; arilo, formilo, alquilcarbonilo C1-6; alquilo C1-6 sustituido en forma opcional; alquiloxicarbonilo C1-6; R2 es OH; halogeno; alquilo C1-6 sustituido en forma opcional, alquenilo C2-6 o alquinilo C2-6; carbonilo sustituido; carboxilo; CN; nitro; amino; amino sustituido; polihalogenometilo; polihalogenometiltio; -S(=O)PR6, C(=NH)R6; R2a es CN; amino, amino sustituido, alquilo C1-6 sustituido en forma opcional; halogeno; alcoxi C1-6 sustituido en forma opcional; carbonilo sustituido; -CH=N-NH-C(=O)-R16; alquiloxi C1-6 sustituido en forma opcional; alquenilo C2-6 sustituido o alquinilo C2-6; -C(=N-O-R8)-alquilo C1-4; R7 o -X-R7; R3 es CN; amino; alquilo C1-6; halogeno; alquiloxi C1-6 sustituido en forma opcional; carbonilo sustituido; -CH=N-NH-C(=O)-R16; alquilo C1-6 sustituido; alquiloxi C1-6 alquilo C1-6 sustituido en forma opcional; alquenilo C2-6 sustituido o alquinilo C2-6; -C(=N-O-R8)-alquilo C1-4; R7; R4 es halogeno; OH; alquilo C1-6 sustituido en forma opcional, alquenilo C2-6 o alquinilo C2-6; cicloalquilo C3-7; alquiloxi C1-6; CON; nitro; polihalogenoalquilo C1-6; polihalogenoalquiloxi C1-6; carbonilo sustituido; formilo; amino; mono- o di(alquil C1-4-)amino o R7; -A-B- es -CR5=N-, -N=N-, -CH2-CH2-, -CS-NH-, -CO-NH-, -CH=CH-; composiciones farmaceuticas que los comprenden; metodos para la preparacion de estos compuestos y estas composiciones; el uso de estos compuestos para la prevencion o el tratamiento de la infeccion por VIH.
MX2007005159A 2004-10-29 2005-10-27 Derivados de pirimidina biciclicos inhibidores del vih. MX2007005159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105419 2004-10-29
PCT/EP2005/055589 WO2006045828A1 (en) 2004-10-29 2005-10-27 Hiv inhibiting bicyclic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2007005159A true MX2007005159A (es) 2007-06-26

Family

ID=34929789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005159A MX2007005159A (es) 2004-10-29 2005-10-27 Derivados de pirimidina biciclicos inhibidores del vih.

Country Status (16)

Country Link
US (5) US8153640B2 (es)
EP (1) EP1807430B1 (es)
JP (1) JP5118972B2 (es)
KR (1) KR20070085286A (es)
CN (1) CN101048410B (es)
AR (1) AR051410A1 (es)
AU (1) AU2005298637B8 (es)
BR (1) BRPI0517272A (es)
CA (1) CA2577588C (es)
ES (1) ES2508766T3 (es)
IL (1) IL180963A (es)
MX (1) MX2007005159A (es)
RU (1) RU2403254C2 (es)
TW (1) TW200630370A (es)
WO (1) WO2006045828A1 (es)
ZA (1) ZA200703444B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
MX2007013715A (es) 2005-05-05 2008-01-28 Ardea Biosciences Inc Diaril-purinas, azapurinas y deazapurinas como inhibidores no nucleosidos de transcriptasa inversa para el tratamiento del virus de inmunodeficiencia humana.
US7951803B2 (en) * 2006-03-09 2011-05-31 Pharmacopeia, Llc 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
WO2008051826A2 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as pkc-theta inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
MX2010008719A (es) * 2008-02-06 2010-09-24 Novartis Ag Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina.
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2011017079A1 (en) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Process for the preparation and purification of etravirine and intermediates thereof
EP2493472B1 (en) 2009-10-26 2016-12-07 Signal Pharmaceuticals, LLC Methods of synthesis and purification of heteroaryl compounds
CN102115452A (zh) * 2009-12-30 2011-07-06 上海特化医药科技有限公司 (e)-3-(3-取代-5-甲基苯基)丙烯腈及其制备方法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011135578A1 (en) 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
CN107157990B (zh) 2011-10-19 2020-01-07 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
UA114496C2 (uk) 2011-12-02 2017-06-26 Сігнал Фармасьютікалз, Елелсі ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ 7-(6-(2-ГІДРОКСИПРОПАН-2-ІЛ)ПІРИДИН-3-ІЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГІДРОПІРАЗИНО[2,3-b]ПІРАЗИН-2(1H)-ОНУ, ЇХ ТВЕРДІ ФОРМИ І СПОСОБИ ЇХ ЗАСТОСУВАННЯ
CN104066734B (zh) 2012-01-28 2017-03-29 默克专利股份公司 ***并[4,5‑d]嘧啶衍生物
EA028462B1 (ru) 2012-02-24 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
EP2872492B1 (en) * 2012-07-12 2018-01-31 Hetero Research Foundation Process for the preparation of rilpivirine using a novel intermediate
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
BR112015016997A2 (pt) 2013-01-16 2017-07-11 Signal Pharm Llc composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
TW201446745A (zh) 2013-02-08 2014-12-16 Celgene Avilomics Res Inc Ｅｒｋ抑制劑及其用途
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
WO2014172426A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382948B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
CA2908353C (en) 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－***－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
JP6401247B2 (ja) 2013-05-06 2018-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ阻害剤としての大員環化合物
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
US20170050936A1 (en) 2013-08-23 2017-02-23 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20160222014A1 (en) * 2013-09-10 2016-08-04 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
DK3177612T3 (da) 2014-08-04 2022-05-16 Nuevolution As Eventuelt fusionerede heterocyclylsubstituerede derivater af pyrimidin, der er anvendelige til behandling af inflammatoriske, metaboliske, onkologiske og autoimmune sygdomme
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
KR101960624B1 (ko) 2014-12-24 2019-03-20 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 이소퀴놀린 화합물
SG11201705192PA (en) * 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
CN107613769A (zh) * 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
KR20230109185A (ko) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
WO2018035061A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
JP7282045B2 (ja) 2017-06-22 2023-05-26 セルジーン コーポレイション Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
EP3870568B1 (en) * 2018-10-25 2023-06-28 Minakem Process for the preparation of rilpivirine
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性の化合物
CN115279757A (zh) 2020-02-19 2022-11-01 法玛西泰股份公司 用于治疗和预防hiv感染的抗病毒药剂的嘧啶系双环化合物
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519605A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CN111303162B (zh) * 2020-04-16 2021-01-22 天津法莫西医药科技有限公司 一种2-氯-7-环戊基-7H-吡咯并[2,3-d]嘧啶-6-羧酸的制备方法
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE21593C (de) Dr. LÖWIG, Prof. in Breslau Verfahren zur Darstellung von Aetznatron und Aetzkali durch Glühen von Strontiumcarbonat oder Kaliumcarbonat mit Eisenoxyd
DD21593A (es) *
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
DK0945443T3 (da) 1998-03-27 2003-06-02 Janssen Pharmaceutica Nv HIV-hæmmende pyrimidinderivater
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
UA70966C2 (uk) * 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Піримідини, що інгібують реплікацію віл
JP5230050B2 (ja) 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
KR100714519B1 (ko) * 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
KR100767272B1 (ko) 2003-05-05 2007-10-17 에프. 호프만-라 로슈 아게 Ｃｒｆ 활성을 갖는 융합 피리미딘 유도체
DK1658292T3 (da) 2003-07-16 2007-11-12 Janssen Pharmaceutica Nv Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer
EP1781659B1 (en) 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CA2553785C (en) 2004-02-14 2011-02-08 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation

Also Published As

Publication number Publication date
AU2005298637A1 (en) 2006-05-04
AU2005298637A8 (en) 2012-12-06
BRPI0517272A (pt) 2008-10-07
US9487518B2 (en) 2016-11-08
AR051410A1 (es) 2007-01-10
US8153640B2 (en) 2012-04-10
JP2008517978A (ja) 2008-05-29
CN101048410B (zh) 2010-06-23
US20080085907A1 (en) 2008-04-10
RU2403254C2 (ru) 2010-11-10
US9802943B2 (en) 2017-10-31
US20180009819A1 (en) 2018-01-11
US20180016281A1 (en) 2018-01-18
IL180963A (en) 2015-06-30
WO2006045828A1 (en) 2006-05-04
IL180963A0 (en) 2007-07-04
AU2005298637B2 (en) 2012-06-28
US20160355519A1 (en) 2016-12-08
EP1807430B1 (en) 2014-07-23
TW200630370A (en) 2006-09-01
AU2005298637B8 (en) 2012-12-06
US10077270B2 (en) 2018-09-18
US10072015B2 (en) 2018-09-11
RU2007119784A (ru) 2008-12-10
ZA200703444B (en) 2008-11-26
CA2577588C (en) 2013-09-10
EP1807430A1 (en) 2007-07-18
US20120190697A1 (en) 2012-07-26
ES2508766T3 (es) 2014-10-16
CN101048410A (zh) 2007-10-03
KR20070085286A (ko) 2007-08-27
CA2577588A1 (en) 2006-05-04
JP5118972B2 (ja) 2013-01-16

Similar Documents

Publication Publication Date Title
MX2007005159A (es) Derivados de pirimidina biciclicos inhibidores del vih.
TW200626560A (en) HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
TW200626574A (en) HIV inhibiting 5-heterocyclyl pyrimidines
AP1610A (en) HIV replication inhibiting pyrimidines.
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
PL378136A1 (pl) Pirymidyny i triazyny hamujące replikacją wirusa HIV
MY176490A (en) Pyrimidine derivatives for the prevention of hiv infection
CA2473864A1 (en) Composition for use in treating patients suffering from movement disorder
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
BR0213522B1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
HUP0201789A2 (hu) A légzőrendszerre ható szinciciális vírus replikációját gátló vegyületek
TW200744595A (en) Quinoline derivatives as antibacterial agents
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06000300A (es) Derivados de pirimidina-2,4-diona como antagonistas del receptor de la hormona de liberacion de gonadotropina.
UA85541C2 (ru) Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
ATE160348T1 (de) Chimuclidine derivate als squalen synthetase inhibitoren
TW200628155A (en) HIV replication inhibiting pyrimidines
CR20230455A (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
TH79598A (th) อนุพันธ์ของไบไซคลิคพิริมิดีนซึ่งยับยั้งเอชไอวี
UA99131C2 (en) N'-(phenyl)-n-(morpholin-4-yl-pyridin-2-yl)-pyrimidine-2,4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions

Legal Events

Date Code Title Description
FG Grant or registration